| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Singh, Urvashi B.
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (1/1 displayed)
Places of action
| Organizations | Location | People |
|---|
article
Breakthrough infection among healthcare personnel following exposure to COVID-19: Experience after one year of the world’s largest vaccination drive
Abstract
<jats:title>A<jats:sc>BSTRACT</jats:sc></jats:title><jats:sec><jats:title>Context:</jats:title><jats:p>The COVID-19 vaccination drive globally was supposedly a game-changing event. However, the emerging variants of the virus and waning immunity over time posed new challenges for breakthrough infections. Standing at the frontline of defense against COVID-19, healthcare personnel (HCP) were vulnerable to such infections.</jats:p></jats:sec><jats:sec><jats:title>Aims:</jats:title><jats:p>This study estimates i) the vaccine breakthrough infections (VBI) among HCP following exposure to COVID-19 cases, and ii) the mean interval between the second dose of vaccine and laboratory-confirmed SARS-CoV-2 infection</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods:</jats:title><jats:p>A cross-sectional study was conducted including 385 HCP with a history of exposure to COVID-19 cases during January and February 2022. Demographic details and clinical and vaccination history were collected from the test forms and the Web-based hospital management system. Laboratory testing of COVID-19 was carried out by real-time RT-PCR test.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The majority of the HCP were males (262; 68.05%) and nurses (180; 46.75%) by occupation. Two doses of vaccines were received by 278 (87.7%) HCP. VBI was confirmed in 185 (66.55%) HCP. No significant difference in VBI between the COVAXIN and COVISHIELD recipients (<jats:italic toggle="yes">P</jats:italic> = 0.69) was observed. The interval between the second dose and confirmed SARS-CoV-2 infection was significantly higher (<jats:italic toggle="yes">P</jats:italic> < 0.00001) in COVAXIN recipients (median 228 days) than in COVISHIELD recipients (median 95 days).</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The incidence of VBI was very high among the HCP, but not statistically different among the COVAXIN and COVISHIELD-recipients. Waning immunity over time suggests boosting immunity with a third dose because of emerging variants.</jats:p></jats:sec>